导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.36% | 2314/4762 |
| 近一周 | -1.59% | 2331/5451 |
| 近一月 | -3.62% | 2684/5408 |
| 近一季 | -6.65% | 2489/5218 |
| 近半年 | -2.52% | 2163/4907 |
| 近一年 | 3.85% | 1970/4387 |
| 近两年 | 51.52% | 1443/2950 |
| 近三年 | 32.31% | 1004/2249 |
| 成立以来 | 50.22% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.34% 2761/4961 |
13.69% 1964/5312 |
- - |
- - |
| 2025 | 21.91% 2010/4813 |
-0.12% 2070/3635 |
1.76% 2174/4076 |
18.86% 2236/4524 |
0.91% 1667/4813 |
| 2024 | 15.38% 937/3463 |
2.46% 775/2808 |
-1.68% 1092/3014 |
16.89% 1321/3129 |
-2.02% 1925/3463 |
| 2023 | -8.43% 1015/2656 |
5.22% 813/2280 |
-4.30% 1132/2385 |
-3.35% 904/2515 |
-5.90% 1550/2655 |
| 2022 | -18.44% 707/2207 |
-13.67% 808/1919 |
6.11% 769/2016 |
-12.78% 781/2113 |
2.08% 1044/2208 |
| 2021 | 1.92% 649/1822 |
-2.31% 617/1255 |
6.18% 763/1330 |
-3.44% 639/1466 |
1.75% 812/1822 |
| 2020 | 36.12% 402/1250 |
-6.44% 485/1028 |
16.41% 441/1067 |
12.57% 377/1164 |
11.02% 568/1184 |
| 2019 | 39.64% 276/1092 |
28.79% 293/739 |
-1.53% 309/788 |
1.44% 401/850 |
8.55% 305/918 |
| 2018 | -23.54% 286/834 |
- - |
-8.92% 255/631 |
-2.36% 284/660 |
-11.43% 293/682 |
| 2017 | 17.73% 221/714 |
- - |
- - |
- - |
- - |
| 2016 | -12.52% 304/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘中证800指数A VS. 长安沪深300非周期A(740101) |